# Multimodal PET/MR imaging of prolonged disorders of consciousness: a pilot feasibility study

**Authors:** Ning Sun, YiWei Liu, Hua Lin, Jing Xiong, Yi He, HuiLin Yang, MingGang Su, Jing He

PMC · DOI: 10.3389/fnins.2026.1761097 · Frontiers in Neuroscience · 2026-02-20

## TL;DR

This study explores brain imaging in patients with prolonged disorders of consciousness to identify biomarkers that could help assess their condition and guide treatment.

## Contribution

The study introduces a pilot feasibility analysis of simultaneous PET/MR imaging to uncover multimodal brain alterations in prolonged disorders of consciousness.

## Key findings

- pDOC patients showed reduced brain activity and metabolism in regions like the posterior and anterior cingulate cortex.
- Multimodal imaging revealed disrupted connectivity in brain networks linked to consciousness.
- Visual cortex activity inversely correlated with visual responsiveness in pDOC patients.

## Abstract

Prolonged disorders of consciousness (pDOC), including vegetative/unresponsive wakefulness state (VS/UWS) and minimally conscious state (MCS), pose significant diagnostic and prognostic challenges. Multimodal neuroimaging has emerged as a promising tool to uncover neural biomarkers that reflect residual brain function and guide management. This pilot feasibility study aimed to preliminarily characterize metabolic, functional, and structural brain alterations in pDOC patients using simultaneous positron emission tomography/magnetic resonance (PET/MR) imaging, and to examine their tentative associations with clinical behavioral responsiveness.

Eight pDOC patients and eight matched healthy controls underwent hybrid 18F-FDG PET/MR scanning. Resting-state fMRI, diffusion tensor imaging (DTI), and FDG-PET were processed to assess amplitude of low-frequency fluctuations (ALFF), fractional anisotropy (FA), and glucose metabolism, respectively. Group differences were analyzed, and correlations with Coma Recovery Scale-Revised (CRS-R) scores were evaluated. Multimodal integration was performed across imaging modalities.

Compared to controls, pDOC patients exhibited reduced ALFF and FDG uptake in the posterior cingulate cortex (PCC) and anterior cingulate cortex (ACC), with exploratory increased ALFF in the visual cortex inversely correlated with visual responsiveness. Functional connectivity analyses revealed attenuated intra- and inter-network connectivity in the DMN, SN, and DAN. FDG-PET identified metabolic hypofunction in the insula, frontal cortex, and cerebellum, while DTI demonstrated widespread white matter FA reductions. Multimodal correspondence revealed partially overlapping abnormalities in the PCC and occipital regions, highlighting candidate hubs that may be relevant to consciousness level and warrant further validation.

Simultaneous FDG-PET/MR was feasible in this pilot pDOC cohort and provided a convergent, multimodal assessment of metabolic-functional-structural alterations. The PCC and occipital visual cortices emerge as key regions linked to consciousness levels. Given the small sample size and cross-sectional design, these findings are preliminary, and warrant validation in larger longitudinal cohorts before clinical translation.

## Full-text entities

- **Diseases:** tumors (MESH:D009369), drug abuse (MESH:D019966), psychiatric disorders (MESH:D001523), TBI (MESH:D000070642), pulmonary infections (MESH:D012141), trauma (MESH:D014947), HL (MESH:C538324), neurodegeneration (MESH:D019636), hyperactivity of the globus pallidus (MESH:D000079564), alcohol addiction (MESH:D000437), paroxysmal sympathetic hyperactivity (MESH:D006948), neurological or (MESH:D009461), metabolic (MESH:D008659), CRS (MESH:D003398), status epilepticus (MESH:D013226), brain death (MESH:D001926), hypoxic encephalopathy (MESH:D002534), neurological diseases (MESH:D020271), unresponsive wakefulness syndrome (MESH:C567934), white matter damage (MESH:D056784), stroke (MESH:D020521), endocrine/metabolic diseases (MESH:D004700), agitation (MESH:D011595), intracranial infections (MESH:D007239), urinary tract infections (MESH:D014552), MCS (MESH:D018458), ICH (MESH:D002543), nervous system damage (MESH:D020196), Prolonged disorders of consciousness (MESH:D003244), brain injury (MESH:D001930), brain-injured (MESH:D001927), DTI abnormalities (MESH:C564543), Hypoxic-Ischemic Encephalopathy (MESH:D020925), hydrocephalus (MESH:D006849), chronic diseases (MESH:D002908), TBSS (MESH:D008569), FA (MESH:D054144), HIE (MESH:D007589), skin defects (MESH:D012868), cognitive impairment (MESH:D003072), CRS-R (MESH:D003128), axonal injuries (MESH:D001480), post-anoxic coma (MESH:D020207), depressed (MESH:D003866)
- **Chemicals:** blood glucose (MESH:D001786), 18F-FDG (MESH:D019788), zolpidem (MESH:D000077334), 18-Fluorodeoxyglucose (-), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963328/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963328/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963328/full.md

---
Source: https://tomesphere.com/paper/PMC12963328